Adjunctive Cannabidiol in Inpatient Buprenorphine Treatment for Opioid Use Disorder: A Pilot Randomized Trial
Adjunctive CBD was safe and well tolerated in combination with buprenorphine. No clear advantage over placebo was observed. Larger trials are needed to determine clinical utility in MOUD treatment.
Authors
- Andy C. Dean
- Frank J. Vocci (ORCID: https://orcid.org/0000-0003-2143-0950)
- Edythe D. London (ORCID: https://orcid.org/0000-0003-3577-7808)
- Gazmend Elezi (ORCID: https://orcid.org/0000-0003-4087-3431)
- Fiona Whelan (ORCID: https://orcid.org/0000-0001-9165-4859)
- Richard De La Garza (ORCID: https://orcid.org/0000-0003-1943-4469)
- Catherine A. Sugar (ORCID: https://orcid.org/0000-0003-2804-7612)
- Larissa J. Mooney (ORCID: https://orcid.org/0000-0003-1556-731X)
- Megan N. McClintick (ORCID: https://orcid.org/0000-0003-3399-733X)
- Hilary Lachoff
- Matthew Torrington
- Julian P. Whitelegge
- Dara Ghahremani
Institutions
- University of California, Los Angeles (US)
- School of the Art Institute of Chicago (US)
- Institute of Medicinal Molecular Design (JP)
- Friends Research Institute (US)
Publication Details
- Journal
- Journal of Addiction Medicine
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1097/adm.0000000000001640
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00